MA39688B1 - Composés hétéroaryle pour le traitement de maladies ophtalmiques - Google Patents

Composés hétéroaryle pour le traitement de maladies ophtalmiques

Info

Publication number
MA39688B1
MA39688B1 MA39688A MA39688A MA39688B1 MA 39688 B1 MA39688 B1 MA 39688B1 MA 39688 A MA39688 A MA 39688A MA 39688 A MA39688 A MA 39688A MA 39688 B1 MA39688 B1 MA 39688B1
Authority
MA
Morocco
Prior art keywords
rbp4
treatment
img
ophthalmic diseases
heteroaryl compounds
Prior art date
Application number
MA39688A
Other languages
English (en)
Other versions
MA39688A (fr
Inventor
Shigekazu Sasaki
Yoshihiro Banno
Masahiro Kamaura
Kazuaki Takami
Koichiro Fukuda
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA39688A publication Critical patent/MA39688A/fr
Publication of MA39688B1 publication Critical patent/MA39688B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention porte sur un composé hétérocyclique ayant une action abaissant la rbp4 supérieure et utile comme médicament pour la prophylaxie ou le traitement d'une maladie ou d'un symptôme médié par une augmentation de rbp4 ou de rétinol fourni par rbp4. Composé représenté par la formule (i): <img file="imga0001.Tif" frnum="0001" he="46" id="ia01" img-content="chem" img-format="tif" inline="no" orientation="portrait" pgnum="0001" wi="113"/> dans laquelle chaque symbole est tel que défini dans la description, ou un sel de celui-ci a une action abaissant la rbp4 supérieure, et est utile comme médicament pour la prophylaxie ou le traitement d'une maladie ou d'un symptôme à médiation par une augmentation de rbp4 ou de rétinol fourni par rbp4.
MA39688A 2014-10-24 2015-10-22 Composés hétéroaryle pour le traitement de maladies ophtalmiques MA39688B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24
PCT/JP2015/079782 WO2016063933A1 (fr) 2014-10-24 2015-10-22 Composé hétérocyclique

Publications (2)

Publication Number Publication Date
MA39688A MA39688A (fr) 2017-08-30
MA39688B1 true MA39688B1 (fr) 2021-02-26

Family

ID=55760964

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053568A MA53568A (fr) 2014-10-24 2015-10-22 Médicaments pour le traitement de maladies ophtalmiques
MA39688A MA39688B1 (fr) 2014-10-24 2015-10-22 Composés hétéroaryle pour le traitement de maladies ophtalmiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053568A MA53568A (fr) 2014-10-24 2015-10-22 Médicaments pour le traitement de maladies ophtalmiques

Country Status (37)

Country Link
US (4) US10214498B2 (fr)
EP (2) EP3848353A1 (fr)
JP (2) JP6588027B2 (fr)
KR (1) KR102490156B1 (fr)
CN (2) CN107108506B (fr)
AR (1) AR104342A1 (fr)
AU (2) AU2015336480B2 (fr)
BR (1) BR112017007138A2 (fr)
CA (1) CA2965465C (fr)
CL (1) CL2017000944A1 (fr)
CO (1) CO2017003699A2 (fr)
CR (1) CR20170160A (fr)
CY (1) CY1123842T1 (fr)
DK (1) DK3210973T3 (fr)
DO (1) DOP2017000098A (fr)
EA (1) EA033446B1 (fr)
EC (1) ECSP17026687A (fr)
ES (1) ES2848999T3 (fr)
HR (1) HRP20210320T1 (fr)
HU (1) HUE053443T2 (fr)
IL (2) IL285105B2 (fr)
LT (1) LT3210973T (fr)
MA (2) MA53568A (fr)
MX (2) MX2017004629A (fr)
MY (1) MY183209A (fr)
PE (1) PE20170669A1 (fr)
PH (1) PH12017500747A1 (fr)
PL (1) PL3210973T3 (fr)
PT (1) PT3210973T (fr)
RS (1) RS61504B1 (fr)
SG (1) SG11201702312UA (fr)
SI (1) SI3210973T1 (fr)
TN (1) TN2017000097A1 (fr)
TW (2) TWI703131B (fr)
UA (1) UA121871C2 (fr)
WO (1) WO2016063933A1 (fr)
ZA (1) ZA201703344B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3210973T1 (sl) 2014-10-24 2021-04-30 Takeda Pharmaceutical Company Limited Heteroarilne spojine za zdravljenje oftalmičnih bolezni
SG11201908691PA (en) 2017-03-20 2019-10-30 Broad Inst Inc Compounds and methods for the treatment of parasitic diseases
EP3829575A4 (fr) * 2018-08-01 2022-07-20 The Trustees of Columbia University in the City of New York Antagonistes de rbp4 pour le traitement et la prévention de la stéatose hépatique non alcoolique et de la goutte
CN111690698A (zh) * 2020-05-19 2020-09-22 浙江工业大学 两步串联流动合成3-（苯并[d][1,3]二氧-5-氨基）丙羟肟酸的方法
CN111690695A (zh) * 2020-05-19 2020-09-22 浙江工业大学 3-苯氨基丙羟肟酸的酶促微流控在线合成方法
WO2022256301A1 (fr) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Méthodes et composés pour traiter des sujets atteints d'une maladie de stargardt
CN116286900B (zh) * 2022-10-28 2024-04-26 昆明理工大学 一种乙酸渗透酶A基因RkAcpa及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (fr) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Composés à base d'oxazol, procédé pour leur préparation et leur utilisation
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2386517A1 (fr) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Derives d'amines
BR0015466A (pt) 1999-11-10 2002-08-06 Takeda Chemical Industries Ltd Composto, prodroga, composição farmacêutica, agentes para evitar ou tratar diabetes mellitus, hiperlipidemia e toler ncia à glicose prejudicada, para regular a função do receptor relacionado a retinóide e para melhorar a resistência à insulina e uso de um composto
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (de) * 2001-10-08 2003-04-24 Consequence Gmbh Verfahren zur Sequenzanalyse von Polypeptiden
EP1437351A4 (fr) 2001-10-19 2005-06-01 Takeda Pharmaceutical Derive d'amine
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1658273B1 (fr) 2003-08-20 2007-01-03 Eli Lilly And Company Composes, procedes et preparations destines a l'apport oral d'un compose peptidique de type glucagon (glp-1) ou d'un peptide agoniste du recepteur 4 de melanocortine (mc4)
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
WO2005120583A2 (fr) 2004-06-14 2005-12-22 Wisconsin Alumni Research Foundation Methode permettant de prevenir ou de traiter l'hypertrophie cardiaque
DE602005008970D1 (de) 2004-06-23 2008-09-25 Sirion Therapeutics Inc Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
US20080033053A1 (en) 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
WO2006042252A2 (fr) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Proteines regulatrices du complement viral pour troubles de la vue
US20090098145A1 (en) 2006-06-22 2009-04-16 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
EP2170306A1 (fr) 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Procédés de traitement de maladies et de troubles véhiculés par la sérotonine
EP2170335A1 (fr) 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Compositions comprenant des inhibiteurs de tryptophane hydroxylase
CA2699773A1 (fr) * 2007-09-27 2009-04-02 Sirion Therapeutics, Inc. Procedes et composes pour le traitement de maladies liees au retinol
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009143390A2 (fr) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Procédés de modulation de l’expression de rbp4
CN102112440A (zh) * 2008-05-30 2011-06-29 武田药品工业株式会社 杂环化合物
AU2010236685A1 (en) * 2009-04-13 2011-12-01 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (RBP4)
KR20120006545A (ko) * 2009-04-16 2012-01-18 다케다 야쿠힌 고교 가부시키가이샤 당뇨병의 예방 또는 치료에 특히 유용한 ｎ―아실―ｎ’―페닐피페라진의 유도체
JP2013509430A (ja) 2009-10-28 2013-03-14 リヴィジョン セラピューティクス，インク． レチンアミドによる皮膚癌の予防
AU2010327936B2 (en) 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
NZ718622A (en) 2010-03-30 2018-03-23 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
EP2642998B1 (fr) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
EP3552664A1 (fr) 2011-05-12 2019-10-16 Proteostasis Therapeutics, Inc. Régulateurs de proteostasis
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (fr) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Ligands de la transthyrétine pouvant inhiber l'interaction de rbp4-ttr dépendante du rétinol pour le traitement de la dégénérescence maculaire liée à l'âge, de la maladie de stargardt et d'autres maladies de la rétine caractérisées par une accumulation excessive de lipofuscine
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014160409A1 (fr) 2013-03-14 2014-10-02 The Trustees Of Columbia University In The City Of New York Antagonistes de rbp4 pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
WO2014153643A1 (fr) 2013-03-26 2014-10-02 The University Of British Columbia Compositions et procédés d'utilisation associés dans le traitement de l'aniridie
CA2941716A1 (fr) 2014-03-07 2015-09-11 The Johns Hopkins University Inhibiteurs de la demethylase (lsd1) specifique d'une lysine d'histone et d'histones desacetylases (hdac)
SI3210973T1 (sl) * 2014-10-24 2021-04-30 Takeda Pharmaceutical Company Limited Heteroarilne spojine za zdravljenje oftalmičnih bolezni
CN107074804B (zh) 2014-10-24 2020-02-18 百时美施贵宝公司 咔唑衍生物
SG11201703188QA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors
WO2016172631A2 (fr) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Inhibiteurs sélectifs de substrats d'enzyme dégradant l'insuline (ide) et utilisations associées
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Also Published As

Publication number Publication date
HUE053443T2 (hu) 2021-06-28
AU2015336480A1 (en) 2017-05-25
SI3210973T1 (sl) 2021-04-30
US20180237404A1 (en) 2018-08-23
SG11201702312UA (en) 2017-05-30
EA201790912A1 (ru) 2017-09-29
AU2020204426A1 (en) 2020-07-23
PT3210973T (pt) 2021-02-12
US20200157062A1 (en) 2020-05-21
PL3210973T3 (pl) 2021-06-28
US20210340114A1 (en) 2021-11-04
DOP2017000098A (es) 2017-07-15
IL285105B2 (en) 2023-03-01
RS61504B1 (sr) 2021-03-31
HRP20210320T1 (hr) 2021-04-30
JPWO2016063933A1 (ja) 2017-08-03
US10975043B2 (en) 2021-04-13
PH12017500747B1 (en) 2017-10-30
ECSP17026687A (es) 2017-09-29
MY183209A (en) 2021-02-18
JP6588027B2 (ja) 2019-10-09
CR20170160A (es) 2017-06-15
EP3210973A4 (fr) 2018-04-25
IL285105B (en) 2022-11-01
TN2017000097A1 (en) 2018-07-04
LT3210973T (lt) 2021-03-25
AU2020204426B2 (en) 2022-02-03
CA2965465C (fr) 2023-08-01
CY1123842T1 (el) 2022-05-27
MX2017004629A (es) 2017-06-30
US20190119225A1 (en) 2019-04-25
JP6995094B2 (ja) 2022-02-21
JP2020007347A (ja) 2020-01-16
CN107108506B (zh) 2022-06-21
KR102490156B1 (ko) 2023-01-18
TWI703131B (zh) 2020-09-01
PH12017500747A1 (en) 2017-10-30
UA121871C2 (uk) 2020-08-10
AU2015336480A2 (en) 2017-06-01
EP3848353A1 (fr) 2021-07-14
MX2021001188A (es) 2021-04-19
IL251695A0 (en) 2017-06-29
EP3210973A1 (fr) 2017-08-30
DK3210973T3 (da) 2021-02-08
US10544111B2 (en) 2020-01-28
EA033446B1 (ru) 2019-10-31
MA39688A (fr) 2017-08-30
TWI749661B (zh) 2021-12-11
EP3210973B1 (fr) 2020-12-02
CL2017000944A1 (es) 2018-01-12
TW201714876A (zh) 2017-05-01
US10214498B2 (en) 2019-02-26
AR104342A1 (es) 2017-07-12
CN107108506A (zh) 2017-08-29
ES2848999T3 (es) 2021-08-13
KR20170067791A (ko) 2017-06-16
CA2965465A1 (fr) 2016-04-28
IL251695B (en) 2021-08-31
ZA201703344B (en) 2018-08-29
AU2015336480B2 (en) 2020-04-02
PE20170669A1 (es) 2017-06-06
MA53568A (fr) 2022-02-23
IL285105A (en) 2021-08-31
BR112017007138A2 (pt) 2017-12-26
CN115197160A (zh) 2022-10-18
TW202042805A (zh) 2020-12-01
WO2016063933A1 (fr) 2016-04-28
CO2017003699A2 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
MA39688B1 (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu&#39;inhibiteur d&#39;oga
MA39246A1 (fr) Composé hétérocyclique fusionné
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
EA201892207A1 (ru) Индолкарбоксамидные соединения
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d&#39;une infection par le virus du vih
MA46337B1 (fr) Composé de pyridine
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
MA52063B1 (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu&#39;inhibiteurs de la kallicréine plasmatique
MD3269370T2 (ro) Compus pirimidinic condensat nou sau sare a acestuia
MA39247A1 (fr) 2-(4-guanidinophenyl)-2-oxo-ethyle substitues inhibiteurs d&#39;enteropeptidase utiles pour le traitement ou la prevention, par ex. L&#39;obesite, le diabete sucre, les troubles de l&#39;alimentation, l&#39;hyperlipidemie, l&#39;hypertension, l&#39;insuffisance cardiaque
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
MA35432B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
MA56553B1 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d&#39;un trouble médié par btk
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l&#39;amélioration ou la prévention d&#39;une maladie virale
MA38078A1 (fr) Dérivé de pyridine
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
TN2017000158A1 (en) Carbazole derivatives
MA41975B1 (fr) Derives d&#39;aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d&#39;alzheimer
MA43231B1 (fr) Bloqueur des canaux sodiques
PE20180204A1 (es) Procedimiento para la preparacion de 2-4-[2-([2-(4-(clorofenil)-1,3-tiazol-4-il]metilsulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxietil-l-alanil-l-alaninato-monohidrocloruro
MA37849A1 (fr) Dérivés de diazépinone à utiliser pour le traitement du syndrome de l&#39;x fragile, de la maladie de parkinson ou de la maladie du reflux
MA39432B1 (fr) Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu&#39;inhibiteur de bace
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside